Therma Bright Inc. announced that it has submitted an application to an independent Research Ethics Board (REB) for approval to conduct a clinical study with the Company's AcuVid TM rapid antigen test for detecting SARS CoV-2 virus in saliva. Approval is expected within a week, at which point Therma will submit a complete package, including the REB review, to Health Canada to conduct the clinical trial. The data generated from this pivotal clinical study will also be used to support Therma's European Union CE mark submission to be initiated shortly. The CE mark will allow sales of the product in Europe and in other countries where a CE mark is required. Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.